Insider Actions
07/24/2019 |
Charles L. Bisgaier Chief Scientific Off. & Chair; Director |
100,000 | Award at $0 per share. | 0 |
07/24/2019 |
Steven R. Gullans President & CEO; Director |
300,000 | Award at $0 per share. | 0 |
07/24/2019 |
Andrew H. Sassine Director |
15,000 | Award at $0 per share. | 0 |
07/24/2019 |
Seth Reno Chief Commercial Officer |
100,000 | Award at $0 per share. | 0 |
07/24/2019 |
Pedro Lichtinger Director |
15,000 | Award at $0 per share. | 0 |
07/24/2019 |
Kenneth W Kousky Director |
15,000 | Award at $0 per share. | 0 |
02/08/2018 |
Steven R. Gullans President & CEO; Director |
71,429 | Acquisition at $7 per share. | 500,003 |
02/08/2018 |
Seth Reno Chief Commercial Officer |
14,286 | Acquisition at $7 per share. | 100,002 |
08/14/2017 |
Jeffrey S. Mathiesen Chief Financial Officer |
3,207 | Derivative/Non-derivative trans. at $3.59 per share. | 11,513 |
08/10/2017 |
Jeffrey S. Mathiesen Chief Financial Officer |
3,000 | Derivative/Non-derivative trans. at $3.59 per share. | 10,770 |
08/10/2017 |
Jeffrey S. Mathiesen Chief Financial Officer |
3,000 | Derivative/Non-derivative trans. at $3.59 per share. | 10,770 |
07/31/2017 |
Charles L. Bisgaier Chief Scientific Off. & Chair; Director |
4,474 | Derivative/Non-derivative trans. at $1.34 per share. | 5,995 |
03/10/2017 |
Steven R. Gullans President & CEO; Director |
52,798 | Acquisition at $9.47 per share. | 499,997 |
03/10/2017 |
Andrew H. Sassine Director |
21,119 | Acquisition at $9.47 per share. | 199,996 |
03/10/2017 |
P. Kent Hawryluk Director |
25,000 | Acquisition at $9.47 per share. | 236,750 |
03/10/2017 |
Pedro Lichtinger Director |
10,559 | Acquisition at $9.47 per share. | 99,993 |
02/01/2017 |
Kenneth W Kousky Director |
110,428 | 0 | |
02/01/2017 |
Kenneth W Kousky Director |
101,406 | 0 | |
08/10/2016 |
Charles L. Bisgaier Chief Scientific Off. & Chair; Director |
51,750 | Acquisition at $10 per share. | 517,500 |
08/10/2016 |
Steven R. Gullans President & CEO; Director |
500,000 | Acquisition at $10 per share. | 5,000,000 |
08/10/2016 |
David Lowenschuss Chief Legal Off. & Secretary |
11,120 | Acquisition at $10 per share. | 111,200 |
08/10/2016 |
Mina Patel Sooch President & CEO; Director |
52,500 | Acquisition at $10 per share. | 525,000 |
08/10/2016 |
Seth Reno Chief Commercial Officer |
4,000 | Acquisition at $10 per share. | 40,000 |
08/10/2016 |
P. Kent Hawryluk Director |
25,000 | Acquisition at $10 per share. | 250,000 |
08/10/2016 |
Pedro Lichtinger Director |
10,000 | Acquisition at $10 per share. | 100,000 |
08/10/2016 |
Kenneth W Kousky Director |
1,000 | Acquisition at $10 per share. | 10,000 |
08/10/2016 |
Jeffrey S. Mathiesen Chief Financial Officer |
4,000 | Acquisition at $10 per share. | 40,000 |
08/10/2016 |
Charles L. Bisgaier Chief Scientific Off. & Chair; Director |
19,228 | Derivative/Non-derivative trans. at $6.71 per share. | 129,019 |
08/10/2016 |
Charles L. Bisgaier Chief Scientific Off. & Chair; Director |
16,144 | Derivative/Non-derivative trans. at $6.71 per share. | 108,326 |
08/10/2016 |
Charles L. Bisgaier Chief Scientific Off. & Chair; Director |
59,561 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2016 |
Steven R. Gullans President & CEO; Director |
306,025 | Derivative/Non-derivative trans. at $6.71 per share. | 2,053,427 |
08/10/2016 |
Mina Patel Sooch President & CEO; Director |
27,141 | Derivative/Non-derivative trans. at $6.71 per share. | 182,116 |
08/10/2016 |
Mina Patel Sooch President & CEO; Director |
11,078 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2016 |
Daniela Carmen Oniciu Vice President |
2,237 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2016 |
Andrew H. Sassine Director |
31,853 | Derivative/Non-derivative trans. at $6.71 per share. | 213,733 |
08/10/2016 |
Andrew H. Sassine Director |
75,080 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2016 |
P. Kent Hawryluk Director |
23,616 | Derivative/Non-derivative trans. at $6.71 per share. | 158,463 |
08/10/2016 |
P. Kent Hawryluk Director |
7,457 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2016 |
Pedro Lichtinger Director |
39,274 | Derivative/Non-derivative trans. at $6.71 per share. | 263,528 |
08/10/2016 |
Kenneth W Kousky Director |
116,891 | Derivative/Non-derivative trans. at $6.71 per share. | 784,338 |
08/10/2016 |
Kenneth W Kousky Director |
95,439 | Derivative/Non-derivative trans. at $0 per share. | 0 |
08/10/2016 |
Jeffrey S. Mathiesen Chief Financial Officer |
3,927 | Derivative/Non-derivative trans. at $6.71 per share. | 26,350 |
08/10/2016 |
Charles L. Bisgaier Chief Scientific Off. & Chair; Director |
6,515 | 43,715 | |
08/10/2016 |
Mina Patel Sooch President & CEO; Director |
1,212 | 8,132 | |
08/10/2016 |
Daniela Carmen Oniciu Vice President |
245 | 1,643 | |
08/10/2016 |
Andrew H. Sassine Director |
8,212 | 55,102 | |
08/10/2016 |
P. Kent Hawryluk Director |
816 | 5,475 | |
08/10/2016 |
Kenneth W Kousky Director |
10,439 | 70,045 |
MarketWatch News on NRBO
-
Gemphire Therapeutics' stock extends slide, plummets 39% premarket after trial halt
- Tomi Kilgore
-
Gemphire's stock on track to open at record low
- Tomi Kilgore
-
Gemphire Therapeutics stock tumbles 17% premarket after trial halt
- Tomi Kilgore
-
Gemphire's stock on track to open at record low
- Tomi Kilgore
-
Gemphire Therapeutics downgraded to market perform from outperform at Raymond James
- Tomi Kilgore
-
Gemphire Therapeutics stock price target raised to $26 from $22 at Raymond James
- Tomi Kilgore
-
Gemphire Therapeutics started at outperform with $22 stock price target
- Tomi Kilgore
Other News on NRBO
-
10-Q: NEUROBO PHARMACEUTICALS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
10-K: NEUROBO PHARMACEUTICALS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
ETRN, PIXY and UONE among mid-day movers
- Seeking Alpha
-
Healthcare names dominate premarket losers list
- Seeking Alpha
-
10-Q: NEUROBO PHARMACEUTICALS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
STAB, RLX and GWH among mid-day movers
- Seeking Alpha
-
CLLS, BBIG and GNLN among pre market gainers
- Seeking Alpha
-
ADVM, SELB and OSUR among pre market gainers
- Seeking Alpha
-
OMER, SMTS and AVIR among mid-day movers
- Seeking Alpha
-
NeuroBo Pharmaceuticals falls 11% amid $14M equity offering
- Seeking Alpha
-
SD, TELL and CEI among pre market gainers
- Seeking Alpha
-
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
- InvestorPlace.com
-
DQ, BTBT and GOTU among pre market gainers
- Seeking Alpha
-
10-Q: NEUROBO PHARMACEUTICALS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
SAVA, MMAT, XAIR among midday movers
- Seeking Alpha
-
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
- InvestorPlace.com
- Loading more headlines...